FTC and 7 states are seeking to hold Martin Shkreli in contempt over pharma ban
The Federal Trade Commission (FTC) and seven states are seeking to hold Martin Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. Shkreli is accused of trading stock in at least 60 pharmaceutical companies and broadcasting investment advice online since his release from prison in 2022.
Why it matters
This action highlights the ongoing efforts to enforce regulatory bans against individuals with a history of corporate misconduct, impacting market integrity and investor confidence in the pharmaceutical sector.
The agency alleges Shkreli traded stock in at least 60 pharmaceutical…
Also covering this story
2 other newsrooms covered this event. We read each version separately.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in